The influence of hyperestrogenism during in vitro fertilization on the fibrinolytic mechanism

International Journal of Fertility and Women's Medicine

Volumn 43, Issue 1, 1998, Pages 34-39

  Lox, Charles ^a,b   Cañez, Melin ^a   Prien, Samuel ^a  

^a TEXAS TECH UNIVERSITY   (United States)

^b TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

Coagulation; Estradiol; Fibrinolysis; In vitro fertilization

Indexed keywords

CHORIONIC GONADOTROPIN; ESTRADIOL; ESTROGEN; FIBRINOLYTIC FACTOR; HUMAN MENOPAUSAL GONADOTROPIN; LEUPRORELIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; PLASMINOGEN ACTIVATOR INHIBITOR 2; TISSUE PLASMINOGEN ACTIVATOR; UROKINASE;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; ESTROGEN BLOOD LEVEL; FEMALE; FERTILIZATION IN VITRO; FIBRINOLYSIS; HUMAN; HUMAN TISSUE; OVARY HYPERSTIMULATION; OVULATION INDUCTION; PRIORITY JOURNAL; THROMBOSIS;

ADULT; ANALYSIS OF VARIANCE; ESTRADIOL; FEMALE; FERTILIZATION IN VITRO; FIBRINOLYSIS; HUMANS; LINEAR MODELS; OVULATION INDUCTION; PLASMINOGEN ACTIVATORS; PLASMINOGEN INACTIVATORS;

EID: 0344474604     PISSN: 1534892X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Jepperson J, Petersen KR, Skouby SO: Effects of newer oral contraceptives on the inhibition of coagulation and fibrinolysis in relation to dosage and type of steroid. Am J Obstet Gynecol 163:396-403, 1990.
2. Speroff L, DeCherny A, Burkman RT, et al: Evaluation of a new generation of oral contraceptives. Obstet Gynecol 81:1034-1037, 1993.
3. Smitz J, Camus M, Devroey P, et al: Incidence of severe ovarian hyperstimulation syndrome after GnRH agonist/HMG superovulation for in-vitro fertilization. Hum Reprod 5:933-937, 1990.
4. Sher G, Salem R, Feinman M, et al: Eliminating the risk of life-threatening complications following over-stimulation with menotropin fertility agents: a report on women undergoing in vitro fertilization and embryo transfer. Obstet Gynecol 81:1009-1011, 1993.
5. Bider D, Menashe Y, Oelsner G, et al: Ovarian hyperstimulation syndrome due to exogenous gonadotropin administration. Acta Obstet Gynecol Scand 68:511-514, 1989.
6. Lox C, Canez M, DeLeon F, et al: Hyperestrogenism induced by menotropins alone or in conjunction with leuprolide acetate in vitro fertilization cycles: the impact on hemostasis. Fertil Steril 63:566-570, 1995.
7. Quehenberger P, Kapiotis S, Pärtan C, et al: Studies on oral contraceptive-induced changes in blood coagulation and fibrinolysis and the estrogen effect on endothelial cells. Ann Hematol 67:33-36, 1993.
8. Cachrimanidou A-C, Hellberg D, Nilsson S, et al: Hemostasis profile and lipid metabolism with long-interval use of a desogestrel-containing oral contraceptive. Contraception 50:153-165, 1994.
9. Dörr PJ, Brommer EJP, Dooijewaard G, et al: Parameters of fibrinolysis in peritoneal fluid and plasma in different stages of the menstrual cycle. Thromb Haemost 70:873-875, 1993.
10. Epifano O, Riminucci M, Manna C, et al: In vitro production of plasminogen activator by human granulosa cells. J Clin Endocrinol Metab 78:174-179, 1994.
11. Montgomery VC, Richard-Davis G, Saleh AA, et al: Fibrinolytic parameters in women undergoing ovulation induction. Am J Obstet Gynecol 169:1549-1553, 1993.
12. Reith A, Booth NA, Moore NR, et al: Plasminogen activator inhibitors (PAI-1 and PAI-2) in normal pregnancies, pre-eclampsia and hydatidiform mole. Br J Obstet Gynaecol 100:370-374, 1993.
13. Kwaan HC: The plasminogen-plasmin system in malignancy. Cancer Metastasis Rev 11:291-311, 1992.
14. Gebara OCE, Mittleman MA, Sutherland P, et al: Association between increased estrogen status and increased fibrinolytic potential in Framingham Off-spring Study. Circulation 91:1952-1958, 1995.